Clinical Trial Update: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

ATH-1017 completed Phase 2 and Phase 3 trials for Alzheimer's disease, with results posted on 2025-04-04. The sponsor for the study is LeonaBio.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ATH-1017

Snippet

Sponsor: LeonaBio | Conditions: Alzheimer Disease, Dementia of Alzheimer Type | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-04-04